LIST OF CONTENTS

NUMBER 1

	I	**Important Announcement to Readers**
Commentaries		
J.-L. Canon, Y. Humblet and *M. Symann*	1	**Resistance to cisplatin: how to deal with the problem?**
F. E. Evans, R. A. Levine and *P. G. Okunieff*	5	**Detection of malignant tumors by ^1H nuclear magnetic resonance spectroscopy of plasma**
M. Iwai, M. Okumoto, R. Nishikawa, Y. Iwai, Y. Takamori and *S. Imai*	9	**DNA rearrangements of the *int* region in spontaneous mouse mammary tumors of SHN/S and SLN/S mice**
W. G. DeGraff, A. Russo, N. Friedman and *J. B. Mitchell*	17	**Misonidazole hypoxic cytotoxicity and chemosensitization in two cell lines with different intracellular glutathione levels**
R. Goel, P. A. Andrews, C. E. Pfeifle, I. S. Abramson, S. Kirmani and *S. B. Howell*	21	**Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy**
E. T. Fossel, H. F. Dvorak, J. M. Carr and *J. McDonagh*	29	**Alteration of aliphatic lipid proton NMR linewidths by malignant tumors in guinea pigs**
P. Lissoni, S. Barni, F. Rovelli, S. Viviani, G. J. M. Maestroni, A. Conti and *G. Tancini*	33	**The biological significance of soluble interleukin-2 receptors in solid tumors**
L. J. Hofland, P. M. van Koetsveld and *S. W. Lamberts*	37	**Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995**
S. Gundersen, S. Kvinnsland, O. Klepp, E. Lund and *H. Høst*	45	**Weekly Adriamycin® vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial**
L.-M. Ching, G. J. Finlay, W. R. Joseph and *B. C. Baguley*	49	**Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells**
B. C. Baguley, P. M. Turner and *L. R. Ferguson*	55	**Protection by inhibitors of multidrug resistance against mitochondrial mutagenesis in *Saccharomyces cerevisiae***
Clinical Trial Summaries		
C. Sessa, T. Cerny, S. Kaye, S. Monfardini, J. Rénard and *F. Cavalli*	61	**A phase II study of iproplatin in advanced or metastatic stomach cancer**
G. Blijham, H. Bleiberg, N. Duez and *M. Buyse*	63	**An EORTC phase II study of sequential methotrexate–fluorouracil in locally advanced or metastatic gastric cancer**
Sounding Board		
C. Billard and *J. Wietzerbin*	67	**On the mechanism of action of interferon-alpha on hairy cell leukemia**
Letter to the Editor		
G. Falkson, H. C. Falkson and *A. S. Alberts*	71	**Severe toxicity with cytorhodin S**
Special Article		
P. Pfeiffer, O. Hansen and *C. Rose*	73	**Systemic cytotoxic therapy of basal cell carcinoma**

NUMBER 2

	I	**Important Announcement to Readers**
I. L. Sziklai, D. Áfra, M. Ordogh, L. Institoris, S. Kerpel-Fronius and *E. Szabo*	79	**The distribution of bromine content of dibromodulcitol in the central nervous system of patients with malignant gliomas**
P. M. Mannucci, M. Cugno, B. Bottasso, F. Marongiu, M. Maniezzo, M. Vaglini and *N. Cascinelli*	83	**Changes in fibrinolysis in patients with localized tumors**
M. L. Boisio, F. Merlo, H. Martines and *M. Esposito*	89	**Blood levels of reduced and oxidized glutathione in malignant and non-malignant human colorectal lesions**

T. Manda, F. Nishigaki, S. Mukumoto, K. Masuda, T. Nakamura and *K. Shimomura*	93	**The efficacy of combined treatment with recombinant human tumor necrosis factor-α and 5-fluorouracil is dependent on the development of capillaries in tumor**
E. Jähde, K.-H. Glüsenkamp and *M. F. Rajewsky*	101	**Protection of cultured malignant cells from mitoxantrone cytotoxicity by low extracellular pH: a possible mechanism for chemoresistance *in vivo***
R. F. Betteridge, A. G. Bosanquet and *E. D. Gilby*	107	**Pharmacokinetics of 2,5-diaziridinyl-3,6-bis (2-hydroxyethylamino)-1,4-benzoquinone (BZQ, NSC 224070) during a Phase I clinical trial**
J. Hemmer	113	***In vitro* bromodeoxyuridine labelling of squamous cell carcinomas of the oral cavity**
O. C. Boerman, W. K. Makkink, C. M. G. Thomas, A. G. J. M. Hanselaar, C. A. Yedema, P. Kenemans and *L. G. Poels*	117	**Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours**
D. B. Smith, R. P. Mosely, R. H. J. Begent, H. B. Coakham, M. G. Glaser, S. Dewhurst, A. Kelly and *K. D. Bagshawe*	129	**Quantitative distribution of ^{131}I-labelled monoclonal antibodies administered by the intra-ventricular route**
Clinical Trial Summaries		
C. Sessa, W. ten Bokkel Huinink, G. Stoter, J. Renard and *F. Cavalli*	137	**Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma**
G. Blackledge, A. van Oosterom, H. Mouridsen, W. P. Steward, J. Buesa, D. Thomas, R. Sylvester and *J. Rouesse*	139	**Doxorubicin in relapsed soft tissue sarcoma: justification of Phase II evaluation of new drugs in this disease**
	143	**Abstracts from the Second International Symposium on "Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents"**
Books Received	199	

NUMBER 3

	I	**Important Announcement to Readers**
	201	**Acknowledgement**
D. W. van Bekkum	205	**Obituary: Luke van Putten**
Perspectives in Cancer Research *J. E. McCormick* and *R. S. McElhinney*	207	**Nitrosoureas from chemist to physician: classification and recent approaches to drug design**
Commentary *P. J. Goodwin, R. Feld, P. Warde* and *R. J. Ginsberg*	223	**The costs of cancer therapy**
L. Brandt, A. Johnson, H. Olsson and *M. Åkerman*	227	**Mitotic activity and survival in advanced non-Hodgkin's lymphoma of unfavourable histology**
C. Luparello, R. Schillaci, I. Pucci-Minafra and *S. Minafra*	231	**Adhesion, growth and cytoskeletal characteristics of 8701-BC breast carcinoma cells cultured in the presence of type V collagen**
C. Scheiber, R. Kiss, Y. de Launoit, P. Sijens and *J. Frühling*	241	**Influence of hormono- and/or chemotherapy on the MXT mouse mammary tumor as monitored by ^{31}P MRS**
H. Yamamoto, T. Miki, T. Oda, T. Hirano, Y. Sera, M. Akagi and *H. Maeda*	253	**Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinyl ether–maleic acid copolymer**
B. Stenkvist and *E. Olding-Stenkvist*	261	**Cytological and DNA characteristics of hyperplasia/inflammation and cancer of the prostate**
A. Binnerts, P. Uitterlinden, L. J. Hofland, P. v. Koetsveld and *S. W. J. Lamberts*	269	**The *in vitro* and *in vivo* effects of human growth hormone administration on tumor growth of rats bearing a transplantable rat pituitary tumour (7315b)**

A. Bélanger, S. Caron, F. Labrie, C. Naldoni, L. Dogliotti and *A. Angeli*	277	**Levels of eighteen non-conjugated and conjugated steroids in human breast cyst fluid: relationships with cyst type**
P. Bolufer, F. Miralles, A. Rodriguez, C. Vazquez, A. Lluch, J. Garcia-Conde and *T. Olmos*	283	**Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics**
N. S. A. Stuart, R. Grundy, C. M. Woodroffe and *M. H. Cullen*	291	**Quality of life after treatment for testicular cancer—the patient's view**
N. Bürki, M. Buser, L. R. Emmons, A. Gencik, M. Häner, J. K. H. Torhorst, W. Weber and *H. Müller*	295	**Malignancies in families of women with medullary, tubular and invasive ductal breast cancer**
S. S. Ottesen, J. Skouv and *J. Kieler*	305	**Reduced HLA-A,B,C expression in tumourigenic v-*raf* transfected human urothelial cells**
S. Kaasa, S. Kvaløy, M. A. Dicato, F. Ries, J. V. Huys, E. Royer and *L. Carruthers*	311	**A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study**
L. A. Emtage, J. George, B. J. Boughton, C. Trethowan and *G. R. P. Blackledge*	315	**Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/month**
M. H. Silbermann, B. v.d. Vecht, G. Stoter, K. Nooter and *J. Verweij*	321	**Combination therapy of ACNU and ifosfamide in tumor bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer**
F. Liewald, R. P. Wirsching, C. Zülke, N. Demmel and *W. Mempel*	327	**Influence of blood transfusions on tumor recurrence and survival rate in colorectal carcinoma**
P. H. B. Willemse, E. van der Ploeg, D. Th. Sleijfer, T. Tjabbes and *H. van Veelen*	337	**A randomized comparison of megestrol acetate (MA) and medroxy-progesterone acetate (MPA) in patients with advanced breast cancer**
P. H. B. Willemse, J. van Lith, N. H. Mulder, J. G. Aalders, J. Bouma, E. G. E. de Vries and D. Th. Sleijfer	345	**Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis**
P. H. B. Willemse, E. G. E. de Vries, N. H. Mulder, J. G. Aalders, J. Bouma and *D. Th. Sleijfer*	353	**Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer**
P. H. B. Willemse, L. D. Dikkeschei, T. Tjabbes, H. van Veelen and *D. Th. Sleijfer*	359	**Adrenal steroids as parameters of the bioavailability of MA and MPA**
A. Jackson and *J. H. Scarffe*	363	**Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone**
N. van Zandwijk, E. Jassem, J. M. G. Bonfrer and *H. van Tinteren*	373	**Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma**
J. Gerain, J. P. Sculier, A. Malengreaux, C. Rykaert and *L. Thémelin*	377	**Causes of deaths in an oncologic intensive care unit: a clinical and pathological study of 34 autopsies**
M. Kashani-Sabet, Y. Lu, L. Leong, K. Haedicke and *K. J. Scanlon*	383	**Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil**
Z. Radovanovic, D. Velimirovic and *T. Naumovic*	391	**Upper urothelial tumours and the Balkan nephropathy**
J.-O. Fernberg, B. Johansson, R. Lewensohn and *H. Mellstedt*	393	**Oral dosage of melphalan and response to treatment in multiple myeloma**
T. Toko, Y. Sugimoto, K. Matsuo, R. Yamasaki, S. Takeda, K. Wierzba, T. Asao and *Y. Yamada*	397	**TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors**
Clinical Trial Summary		
D. D. von Hoff, P. J. Goodman, C. A. Presant, R. L. Ruxer, J. S. Macdonald, J. J. Costanzi, R. L. Stephens and *S. J. Vogel*	405	**A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma**
Letter to the Editor		
H.-J. Eichhorn	409	**Systemic (hemibody) irradiation in small cell lung cancer**
Special Article	411	**General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe**

NUMBER 4

	415	The Editors
Comments and Critique		
	416	A new journal from a new Europe
	417	Publisher's note
	417	Professor Henri Tagnon
J. P. Armand and E. Cvitkovic	417	Suramin: a new therapeutic concept
H. Bartelink and J. Jassem	419	Early presentation of results in clinical trials: an ethical dilemma for medicine and science
G. E. Adams	420	The clinical relevance of tumour hypoxia
Fax Communication		
A. T. Van Oosterom, E. A. De Smedt, L. J. Denis, E. A. de Bruijn and C. Mahler	422	Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease
Papers		
V. Fantl, M. A. Richards, R. Smith, G. A. Lammie, G. Johnstone, D. Allen, W. Gregory, G. Peters, C. Dickson and D. M. Barnes	423	Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer
Y. D. Senturia and C. S. Peckham	429	Children fathered by men treated with chemotherapy for testicular cancer
M. Chatterjee and A. L. Harris	432	Enhancement of Adriamycin® cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adr^r by toremifene and its modulation by alpha$_1$ acid glycoprotein
J.-P. Brouillet, C. Theillet, T. Maudelonde, A. Defrenne, J. Simony-Lafontaine, J. Sertour, H. Pujol, P. Jeanteur and H. Rochefort	437	Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-*myc*, c-*erb*-B-2 and *int*-2 oncogene amplification and node invasiveness
J. Andersen, S. M. Thorpe, W. J. King, C. Rose, I. Christensen, B. B. Rasmussen and H. S. Poulsen	442	The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays
P. Price, S. J. Hogan and A. Horwich	450	The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time—I. Theoretical basis and practical application
P. Price, S. J. Hogan, J. M. Bliss and A. Horwich	453	The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time—II. Prognostic significance in patients treated by chemotherapy
S. M. Bentzen, I. Balslev, M. Pedersen, P. S. Teglbjaerg, F. Hanberg-Sørensen, J. Bone, N. O. Jacobsen, A. Sell, J. Overgaard, K. Bertelsen, E. Hage, C. Fenger, O. Kronborg, L. Hansen, H. Høstrup and B. Norgaard-Pedersen	457	Blood transfusion and prognosis in Dukes' B and C colorectal cancer
D. M. Tait, H. Thornton-Jones, H. J. G. Bloom, J. Lemerle and P. Morris-Jones	464	Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I)
Specialist Interest Articles		
E. M. J. J. Berns, A. L. G. Schuurmans, J. Bolt, D. J. Lamb, J. A. Foekens and E. Mulder	470	Antiproliferative effects of suramin on androgen responsive tumour cells
P. Carde, L. Da Costa, L. Manil, M. Pfreundschuh, J.-D. Lumbroso, J.-C. Saccavini, B. Caillou, M. Ricard, F. Boudet, M. Hayat, V. Diehl and C. Parmentier	474	Immunoscintigraphy of Hodgkin's disease: *in vivo* use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines
H. Hamed, D. Y. Wang, J. W. Moore, G. M. G. Clark and I. S. Fentiman	479	Growth factor and electrolyte concentration in human breast cyst fluid
L. C. Lai, S. A. Dunkley, M. J. Reed, M. W. Ghilchik, N. A. Shaikh and V. H. T. James	481	Epidermal growth factor and oestradiol in human breast cyst fluid
D. M. Geddes, L. Dones, E. Hill, K. Law, P. G. Harper, S. G. Spiro, J. S. Tobias and R. L. Souhami	484	Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial
G. Milano, A. Thyss, F. Serre Debeauvais, G. Laureys, Y. Benoit, A. Deville, C. Dutour, A. Robert, J. Otten, C. Behar and D. Frappaz	492	CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m^2 methotrexate

S. A. Grossman, D. E. Weissman, H. Wang, M. R. Gilbert, M. L. Updike, V. Walton and M. Wharam	495	Early diagnosis of spinal epidural metastases using out-patient computed tomographic myelography
Feature Articles		
Sir Richard Doll	500	Are we winning the fight against cancer? An epidemiological assessment
W. J. Gullick	509	New developments in the molecular biology of breast cancer
J. C. Knight	511	The molecular genetics of soft tissue sarcomas
W. T. Beck	513	Multidrug resistance and its circumvention
G. J. Peters, H. M. Pinedo, W. Ferwerda, T. W. de Graaf and W. van Dijk	516	Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?
Science Watchers		
P. N. Goodfellow	524	Cancer, the Genome Project and HUGO
News	524	
Letters		
O. Wetter, D. Brandhorst and W. Reiter	541	Leu-19 in myeloma—a new role for an old antibody
H. S. Reinhold, Ch. Zurcher and A. E. van den Berg-Blok	541	Differential heat sensitivity of tumour microvasculature
P. J. McKay, J. G. Docherty G. la Ferla and N. P. Lucie	543	Carcinoma of the small intestine following treated acute myeloid leukaemia
K. Mattson, V. Kinnula, P. Maasilta, M. Kajanti and A. Niiranen	544	Phase II study of trimetrexate and cyclophosphamide in previously untreated patients with inoperable non-small cell lung cancer
F. Bach, J. Vibe-Petersen, J. B. Sørensen, P. Dombernowsky and H. H. Hansen	545	Phase II trial of TCNU and vindesine in patients with adenocarcinoma of the lung
T. Yoshida, N. Okazaki, M. Yoshino, H. Ohkura and Y. Shimada	545	Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma

NUMBER 5

Comments and Critique		
P. Boyle	547	SEARCH programme of the International Agency for Research on Cancer
M. Richonnier	549	Europe against Cancer
	550	New EORTC headquarters
Fax Communication		
K. S. Gulliya, T. Chanh, J. Newman, S. Pervaiz and J. L. Matthews	551	Preactivation—a novel antitumour and antiviral approach
Papers		
V. B. Løgager, A. Vestergaard, J. Herrstedt, H. S. Thomsen, K. Zedeler and P. Dombernowsky	553	The limited value of routine chest X-ray in the follow-up of stage II breast cancer
S. Ciatto, A. Biggeri, M. Rosselli Del Turco, D. Bartoli and A. Iossa	555	Risk of breast cancer subsequent to proven gross cystic disease
J. Schütte, H. T. Mouridsen, W. Stewart, A. Santoro, A. T. van Oosterom, R. Somers, G. Blackledge, J. Verweij, P. Dombernowsky, D. Thomas and R. Sylvester	558	Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma
F. Ravagnani, S. Siena, M. Bregni, G. Sciorelli, A. M. Gianni and G. Pellegris	562	Large scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF
T. J. McMillan, T. Kalebic, G. R. Stark and I. R. Hart	565	High frequency of double drug resistance in the B16 melanoma cell line
M. V. Pimm and R. W. Baldwin	567	Syngeneic anti-idiotypic antibody prevents localization of a murine monoclonal antibody in human tumour xenografts

Specialist Interest Articles		
EORTC International Antimicrobial Therapy Cooperative Group	569	Gram-positive bacteraemia in granulocytopenic cancer patients
S. M. O'Reilly, M. A. Richards and R. D. Rubens	574	Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival
M. Barak, M. Steiner, B. Finkel, J. Abrahamson, S. Antal and N. Gruener	577	CA-15.3, TPA and MCA as markers for breast cancer
R. C. A. A. van Schie, P. H. M. de Mulder, H. van Rennes, H. G. G. Verstraten and D. J. Th. Wagener	581	Effects of doxorubicin on maturation of human monocytes in adherent and non-adherent cultures
G. J. Finlay and B. C. Baguley	586	Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II
B. K. Sinha, P. M. Politi, H. M. Eliot, D. Kerrigan and Y. Pommier	590	Structure–activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposide
C. W. E. Redman, G. R. Blackledge, K. Kelly, J. Powell, E. J. Buxton and D. M. Luesley	593	Early serum CA125 response and outcome in epithelial ovarian cancer
O. Merimsky, I. Reider-Groswasser, M. Inbar and S. Chaitchik	596	Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma
T. Tominaga, Y. Yoshida, K. Shimozuma, K. Hayashi and G. Kosaki	600	Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats
F. J. Cohen, A. Manni, P. Glikman, M. Bartholomew and L. Demers	603	Interactions between growth factor secretion and polyamines in MCF-7 breast cancer cells
K. Pollow, M. Juchem, H. J. Grill, W. Elger, S. Beier, K. Schmidt-Gollwitzer and B. Manz	608	Lack of binding of gestodene to estrogen receptor in human breast cancer tissue
G. Gadeholt, S. Kruse, L. Halsteinslid and E. Sletten	611	Proton nuclear magnetic resonance spectroscopy of serum lipoproteins in rabbits with implanted VX-2 carcinoma
E. Sletten, O. M. Kvalheim, S. Kruse, M. Farstad and O. Søreide	615	Detection of malignant tumours by multivariate analysis of proton magnetic resonance spectra of serum
H. C. Schouten, W. G. Sanger, D. D. Weisenburger and J. O. Armitage	618	Chromosomal abnormalities in patients with non-cutaneous T-cell non-Hodgkin's lymphoma
A. Alama, M. Costantini, L. Repetto, P. F. Conte, J. Serrano, A. Nicolin, F. Barbieri, A. Ardizzoni and P. Bruzzi	622	Thymidine labelling index as prognostic factor in resected non-small cell lung cancer
H. A. M. Sinnige, D.Th. Sleijfer, E. G. E. de Vries, P. H. B. Willemse and N. H. Mulder	625	Modification of 5-fluorouracil activity by high-dose methotrexate or leucovorin in advanced colorectal carcinoma
Feature Articles		
J. C. Macartney and R. S. Camplejohn	635	DNA flow cytometry of non-Hodgkin's lymphomas
C. Kinnon and R. J. Levinsky	638	Gene therapy for cancer
F. R. Balkwill, M. S. Naylor and S. Malik	641	Tumour necrosis factor as an anticancer agent
News	644	
Letters		
W. G. Jones, S. D. Fosså, A. C. Verbaeys, J.-P. Droz, J. G. M. Klijn, E. Boven, M. de Pauw and R. Sylvester	646	Low-dose fortnightly methotrexate in advanced prostate cancer
R. J. Kinders and G. M. Hass	647	Interference in immunoassays by human anti-mouse antibodies
M. Di Stasi, G. Sbolli, F. Fornari, L. Cavanna, G. Civardi, S. Rossi, E. Buscarini and L. Buscarini	648	Hepatocellular carcinoma associated with other primary malignancies
J. W. M. Krulder, L. T. Vlasveld and R. Willemze	649	Erythema and swelling of ears after treatment with cytarabine for leukemia
K. H. N. Veenhof, M. George, M. Forni, S. Tumolo, N. Rotmensz and J. B. Vermorken	650	Mitoxantrone in advanced and/or recurrent endometrial carcinoma
P. Koistinen, V. Kinnula and T. Timonen	651	Aplastic anaemia as a paraneoplastic syndrome in lung cancer
	651	Correction

NUMBER 6

Comments and Critique

J. R. Yarnold 653 Breast conservation and management of early breast cancer

I. S. Fentiman 655 Breast cancer prevention with tamoxifen. The role of tamoxifen in the prevention of breast cancer

A. Costa and R. R. Love 656 Breast cancer prevention with tamoxifen. The Madison Meetings

R. A. Weiss 657 The conundrum of Kaposi's sarcoma

E. G. E. de Vries and J. G. Zijlstra 659 Morpholinyl anthracyclines: option for reversal of anthracycline resistance

S. A. Narod 661 Radiation, genetics and childhood leukaemia

Fax Communication

H. M. Coley, P. R. Twentyman and P. Workman 665 9-alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance

Papers

U. Veronesi, A. Banfi, B. Salvadori, A. Luini, R. Saccozzi, R. Zucali, E. Marubini, M. Del Vecchio, P. Boracchi, S. Marchini, M. Merson, V. Sacchini, G. Riboldi and G. Santoro 668 Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial

U. Veronesi, F. Volterrani, A. Luini, R. Saccozzi, M. Del Vecchio, R. Zucali, V. Galimberti, A. Rasponi, E. Di Re, P. Squicciarini and B. Salvadori 671 Quadrantectomy versus lumpectomy for small size breast cancer

E. Van Limbergen, E. Van der Schueren, W. Van den Bogaert and J. Van Wing 674 Local control of operable breast cancer after radiotherapy alone

T. J. Powles, C. R. Tillyer, A. L. Jones, S. E. Ashley, J. Treleaven, J. B. Davey and J. A. McKinna 680 Prevention of breast cancer with tamoxifen—an update on the Royal Marsden Hospital pilot programme

J. Cuzick, A. Singer, B. L. De Stavola and J. Chomet 684 Case-control study of risk factors for cervical intraepithelial neoplasia in young women

A. G. Kamthan, M. J. Lind, N. Thatcher, W. P. Steward, M. H. Bronchud, M. R. Ranson and R. Stout 691 Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis

Z. Wang, M.-Y. Yin, X. X. Xie, P. Yang, H. Sato, G. Mayers, C. Riobowal and H. D. Preisler 694 Proto-oncogene expression in differentiating and non-differentiating chronic myelogenous leukaemia cells

N. Bendsöe, M. Dictor, J. Blomberg, S. Ågren and K. Merk 699 Increased incidence of Kaposi sarcoma in Sweden before the AIDS epidemic

Specialist Interest Articles

S. G. Allan, M. E. Stewart, S. Love, M. A. Cornbleet, J. F. Smyth and R. C. F. Leonard 703 Prognosis at presentation of small cell carcinoma of the lung

P. K. Maasilta, J. K. Rautonen, M. T. Mattson and K. V. Mattson 706 Quality of life assessment during chemotherapy for non-small cell lung cancer

L. R. Ferguson, C. M. Hill and B. C. Baguley 709 Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent

B. D'Avanzo, E. Negri, C. La Vecchia, A. Gramenzi, C. Bianchi, S. Franceschi and P. Boyle 714 Cigarette smoking and bladder cancer

V. C. Jordan, M. K. Labábidi and D. M. Mirecki 718 Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice

M. Toi, H. Mukaida, T. Wada, N. Hirabayashi, T. Toge, T. Hori and K. Umezawa 722 Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice

E. J. Katz, J. S. Vick, K. M. Kling, P. A. Andrews and S. B. Howell 724 Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells

E. Diaz-Rubio, E. Aranda, M. Martin, R. Gonzalez-Mancha, J. Gonzalez-Larriba and I. Barneto 727 Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer

K. Nooter, A. de Vries, A. C. M. Martens and A. Hagenbeek 729 Effect of cyclophosphamide pretreatment on daunorubicin in rat acute leukaemia model

W. Siegert, C. Beutler, K. Langmach, C. Keitel and C. A. Schmidt 733 Differential expression of the oncoproteins c-myc and c-myb in human lymphoproliferative disorders

N. van Zandwijk, E. Jassem, R. Dubbelmann, M. C. P. Braat and P. Rumke	738	Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma
V. Kinnula, K. Cantell and K. Mattson	740	Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma
M. C. Walker, S. Povey, J. M. Parrington, P. N. Riddle, R. Knuechel and J. R. W. Masters	742	Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines
I. A. Tabbara, W. A. Grosh, W. A. Andersen, P. T. Taylor, S. S. Hahn and F. M. Stewart	748	Treatment of small-cell carcinoma of the cervix with weekly combination chemotherapy
Feature Articles		
D. M. Tait and A. E. Nahum	750	Conformal therapy
U. Metzger	753	Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference
G. Los and J. G. McVie	755	Experimental and clinical status of intraperitoneal chemotherapy
News	763	
Letters		
M. P. Pimm and T. M. Morris	764	Growth rates of human tumours in nude mice
A. Hovestadt, Th. C. M. van Woerkom and Ch. J. Vecht	765	Frequency of neurological disease in a cancer hospital
M. J. Everard, V. M. Macaulay, T. Min, J. L. Millar and I. E. Smith	766	Small cell lung cancer cell line from histologically and immunocytochemically negative bone marrow
P. Lissoni, G. Tancini, C. Archili, R. Rescaldani, G. Cattaneo, S. Crispino and S. Barni	767	Changes in T lymphocyte subsets after single dose epirubicin
R. von Hirschhausen, B. Steinke and J. G. Saal	768	Treatment of advanced Hodgkin's disease with lomustine, etoposide, and prednimustine
P. A. van Liessum, C. Seynaeve, P. H. de Mulder, S. Kaasa, E. Lane-Allman, L. V. Beex and J. Verweij	769	Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin
A. Dupont, H. Boucher, L. Cusan, Y. Lacourciere, J. Emond and F. Labrie	770	Octreotide and bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with flutamide and castration
J. Hardy, A. Jones, M. E. Gore, C. Viner, P. Selby and E. Wiltshaw	771	Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor

NUMBER 7

Comments and Critique		
J. R. Yarnold, P. J. Hoskin and S. N. Powell	773	Study design in the evaluation of combined radiotherapy plus chemotherapy
W. Van den Bogaert	776	Fractionation in radiotherapy
Fax Communications		
N. R. Lemoine, F. S. Wyllie, J. R. Lillehaug, S. L. Staddon, C. M. Hughes, R. Aasland, J. Shaw, J. E. Varhaug, C. L. Brown, W. J. Gullick and D. Wynford-Thomas	777	Absence of abnormalities of the c-*erbB*-1 and c-*erbB*-2 proto-oncogenes in human thyroid neoplasia
J. C. Horiot, R. Le Fur, T. N'Guyen, C. Chenal, S. Schraub, S. Alfonsi, G. Gardani, W. Van den Bogaert, S. Danczak, M. Bolla, M. van Glabbeke and M. de Pauw	779	Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial
Papers		
S. Franceschi, C. la Vecchia, E. Negri, F. Parazzini and P. Boyle	781	Breast cancer risk and history of selected medical conditions linked with female hormones
H. Sumiya, M. Masai, S. Akimoto, R. Yatani and J. Shimazaki	786	Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers
J. E. Pontin, H. Hamed, I. S. Fentiman and J. R. Idle	790	Cytochrome P450dbl phenotypes in malignant and benign breast disease
M. W. Madsen and P. Briand	793	Relationship between tumorigenicity, *in vitro* invasiveness, and plasminogen activator production of human breast cell lines

J.-L. Pujol, J.-F. Rossi, T. Le Chevalier, J.-P. Daurès, P. Rouanet, J.-Y. Douillard, J.-B. Dubois, R. Arriagada, H. Mary, P. Godard and F.-B. Michel	798	Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer

Specialist Interest Articles

I. Gàti, M. Bergström, G. Westerberg, K. Csòka, C. Muhr and J. Carlsson	802	Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids
M. C. Etienne, J. L. Fischel, G. Milano, P. Formento, J. L. Formento, M. Francoual, M. Frenay and M. Namer	807	Steroid receptors in human osteoblast-like cells
R. Sandström, J. Gelin and K. Lundholm	811	The effect of indomethacin on food and water intake, motor activity and survival in tumour-bearing rats
X. F. Hu, M. de Luise, T. J. Martin and J. R. Zalcberg	814	Effect of cyclosporin and verapamil on the cellular kinetics of daunorubicin
J. D. Hainsworth, D. H. Johnson, S. R. Frazier and F. A. Greco	818	Chronic daily administration of oral etoposide in refractory lymphoma
M. Spielmann, P. Kerbrat, T. Delozier, P. Fumoleau, A. Monnier, B. Chevallier, Ph. Bastit, M. Namer, A. Cattan, P. Lucas, H. Roche, Ch. Chevreau, M. Mousseau, B. Coiffier, M. J. Goudier and P. Herait	821	Pirarubicin in advanced breast cancer: a French cooperative phase II study
J. R. Hardy, T. J. Powles, I. R. Judson, H. D. Sinnett, S. E. Ashley, R. C. Coombes and C. L. Ellin	824	Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer
L. Prayer, H. Winkelbauer, N. Gritzmann, F. Winkelbauer, M. Helmer and H. Pehamberger	827	Sonography versus palpation in the detection of regional lymph-node metastases in patients with malignant melanoma
L. J. Vatten and S. Kvinnsland	830	Cigarette smoking and risk of breast cancer: a prospective study of 24 329 Norwegian women
W. Schroyens, E. Tueni, P. Dodion, R. Bodecker, F. Stoessel and J. Klastersky	834	Validation of clinical predictive value of *in vitro* colorimetric chemosensitivity assay in head and neck cancer
R. M. J. Ings, A. J. Gray, A. R. Taylor, B. H. Gordon, M. Breen, M. Hiley, R. Brownsill, N. Marchant, R. Richards, D. Wallace, T. Hughes, R. Thomas, J. Williams, C. Lucas and D. B. Campbell	838	Disposition, pharmacokinetics, and metabolism of ^{14}C-fotemustine in cancer patients

Feature Articles

U. Veronesi	843	NIH consensus meeting on early breast cancer
G. Bonadonna	844	Adjuvant chemotherapy in node-negative breast cancer

News 845

Letters

A. R. Dixon, J. F. R. Robertson, E. Athanassiou, L. Jackson and R. W. Blamey	847	Weekly low dosage epirubicin in advanced breast cancer
D. D. Von Hoff, B. A. Blumenstein, T. W. Pollock, E. D. Crawford, J. K. Weick, J. T. Guy, M. Eisenberger, W. S. Fletcher and R. B. Natale	848	Methylglyoxal bis-guanylhydrazone in advanced bladder cancer
E. Marcuello, M. A. Izquierdo, J. R. Germá, C. Solá, L. de Andres, M. Sanchez, F. Sampedro and J. J. L. López	849	Carboplatin for advanced bladder cancer
R. Coleman, K. Towlson, E. Wiltshaw, M. Slevin, P. Blake, R. Stein, R. Coombes and P. Harper	850	Epirubicin for pretreated advanced ovarian cancer
W. Scheithauer, G. Kornek, K. Haider and D. Depisch	851	Unresponsiveness of pancreatic adenocarcinoma to antioestrogen therapy
M. Geuna, A. Linari and G. Bussolati	852	Cancer cells in effusions and increases in T-activated lymphocytes
B. Persson, B. Jeppsson, M. Hellström, D. Westholm and S. Bengmark	853	Long-term use of an implantable venous catheter
T. Economopoulos, C. Alexopoulos, N. Stathakis, E. Papageorgiou, D. Karakassis, S. Styloyannis, J. Dervenoulas, S. Tsussis and S. Raptis	855	Primary gastric lymphoma
B. G. Taal, W. W. ten Bokkel Huinink, H. R. Franklin and J. G. McVie	856	5-fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results

J. H. Schornagel, J. Verweij, P. H. M. de Mulder, J. Wildiers, A. Kirkpatrick and F. Cognetti	857	Acute blindness during treatment of recurrent or metastatic nasopharyngeal carcinoma with doxorubicin and CCNU
Ph. Colombat, P. Biron, J. P. Laporte, J. Y. Cahn, P. Herve, N. C. Gorin, J. P. Lamagnere and Th. Philip	858	BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas
	858	Correction

NUMBER 8

Comments and Critique		
C. Davis	859	Meningiomas and sex hormones
J. Waxman and H. Thomas	860	Is the outlook changing for patients with renal cell cancer?
Fax Communication		
Y. C. Smart, P. A. Tooney, M. L. Farrelly, J. H. Brien and R. C. Burton	863	Natural cytotoxic cells and tumour surveillance *in vivo*
Papers		
B. Salvadori, P. Squicciarini, D. Rovini, S. Orefice, S. Andreola, F. Rilke, L. Barletta, S. Menard and M. I. Colnaghi	865	Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients
S. Olivier, P. Formento, J. L. Fischel, M. C. Etienne and G. Milano	867	Epidermal growth factor receptor expression and suramin cytotoxicity *in vitro*
M. Binder, H. Pehamberger, A. Steiner and K. Wolff	871	Elective regional lymph node dissection in malignant melanoma
Specialist Interest Articles		
G. Carlsson, W. Graf, B. G. Gustavsson, B. Glimelius, L. Påhlman and P. C. Spears	874	Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer
W. H. Allum, A. J. Jewkes, E. Lanchbury, S. Darby, F. Macdonald and T. O'Brien	876	Biodegradable emboli and antibody targetting of colorectal and gastric hepatic metastases: A pilot study
S. M. Grunberg, S. Groshen, D. C. Robinson, L. L. Stevenson and P. E. Sanderson	879	Correlation of anti-emetic efficacy and plasma levels of ondansetron
S. M. Langan-Fahey, D. C. Tormey and V. C. Jordan	883	Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
R. R. Mehta and G. D. Hart	888	Cellular retinol binding protein and breast carcinoma
E. Teske, G. R. Rutteman, P. van Heerde and W. Misdorp	891	Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma
B. Betsch, M. R. Berger, B. Spiegelhalder, D. Schmähl and G. Eisenbrand	895	An oestradiol-linked nitrosourea and site-directed chemotherapy in mammary carcinoma
A. Harstrick, H.-J. Schmoll, J. Casper, H. Wilke and H. Poliwoda	898	Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents
C. C. Scholz, D. P. Berger, B. R. Winterhalter, H. Henß and H.-H. Fiebig	901	Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts
J. Nordenberg, A. Novogrodsky, E. Beery, M. Patia, L. Wasserman and A. Warshawsky	905	Anti-proliferative effects and phenotypic alterations induced by 8-hydroxyquinoline in melanoma cell lines
T. C. K. Chan and S. B. Howell	907	Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity
Feature Articles		
L. Dewit, R. Moss and D. Gabel	912	New developments in neutron capture therapy
H. S. Reinhold and J. Overgaard	915	Hyperthermia in clinical oncology
News	916	
Letters		
S. Paydaş, Ö. Sargin, S. Özbek and E. Gürbüz	919	Ferritin levels in malignant effusions: a useful marker?

J. P. Sculier, J. Klastersky, P. Libert, P. Ravez, D. Brohee, G. Vandermoten, J. Michel, J. Thiriaux, G. Bureau, J. Schmerber, R. Sergysels and A. Coune for the European Lung Cancer Working Party	919	Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer
O. Merimsky and S. Chaitchik	921	Interferon plus vinblastine in renal carcinoma patients who had failed on interferon alone
S. Culine, M. Ghosn and J.-P. Droz	922	Inappropriate antidiuretic hormone secretion induced by ifosfamide
K. Gietzen, F. Abdallah and G. Bai	922	Inhibition of tumour cell growth by a novel dihydropyridine derivative
W. Scheithauer, G. Kornek, K. Haider and D. Depisch	923	Amonafide in metastatic colorectal carcinoma
S. Bastuji-Garin, O. Chosidow, P. Lang, J.-C. Roujeau and J. Revuz	924	Transient proteinuria during interleukin-2 therapy
R. P. de Dycker, T. Schumacher and R. L. A. Neumann	925	High-dose interferon-beta in treatment of spindle-cell sarcoma of breast
	925	Correction

NUMBER 9

Comments and Critique

S. Dische	927	Continuous, hyperfractionated, accelerated radiotherapy (CHART)
M. H. Bronchud	928	What can we expect from myeloid growth factors?

Fax Communication

N. F. Sullivan	930	Non-tumorigenicity of Bloom's syndrome lymphoblastoid cell lines in immunodeficient mice

Papers

B. Biesma, E. G.E. de Vries, P. H.B. Willemse, W. J. Sluiter, P. E. Postmus, P. C. Limburg, A. C. Stern and E. Vellenga	932	Efficacy and tolerability of recombinant human granulocyte–macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever
A. Ardizzoni, M. R. Sertoli, A. Corcione, M. C. Pennucci, E. Baldini, E. Intra, M. Ferrarini, R. Rosso, P. Mazzanti and V. Pistoia	937	Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study
M. van Ballegooijen, M. A. Koopmanschap, G. J. van Oortmarssen, J. D. F. Habbema, K. Th. N. Lubbe and H. M. A. van Agt	941	Diagnostic and treatment procedures induced by cervical cancer screening

Specialist Interest Articles

F. Kury, G. Sliutz, M. Schemper, G. Reiner, A. Reiner, R. Jakesz, F. Wrba, R. Zeillinger, W. Knogler, J. Huber, H. Holzner and J. Spona	946	HER-2 oncogene amplification and overall survival of breast carcinoma patients
P. McCulloch, G. D. O. Lowe, J. T. Douglas, G. D. Murray and W. D. George	950	Haemostatic abnormalities and outcome in patients with operable breast cancer
P. Lissoni, A.L. Sormani, G. Tancini, G. Cattaneo, C. Archili, D. Mandelli, S. Crispino, F. Paolorossi and S. Barni	953	Postoperative hyperprolactinaemia and early recurrence rate in breast cancer
T. A. Aasmundstad and O. A. Haugen	956	DNA ploidy in intraductal breast carcinomas
H. D. Preisler, R. Agarwal, H. Sato, P. K. Singh, Z. Wang and A. A. Sandberg	960	Studies of proto-oncogene expression in the chronic and blastic phases of chronic myelogenous leukemia
M. Shirai, S. Watanabe and M. Nishioka	965	Intratumoral injection of OK432 and lymphokine-activated killer activity in peripheral blood of patients with hepatocellular carcinoma
J. Marrink, D. Th. Sleijfer, E. G. E. de Vries and H. Schraffordt Koops	969	Alpha-fetoprotein–lectin binding as a marker of tumour activity or liver damage
M. A. Siimes, I. Elomaa and A. Koskimies	973	Testicular function after chemotherapy for osteosarcoma
J. Kärkkäinen, E. Vesterinen, U. -H. Stenman, H. Adlercreutz, U. Nieminen and O. Widholm	975	Comparison of mass spectrometry and radioimmunoassay to measure medroxyprogesterone acetate in patients with endometrial cancer

H. Brenner, C. Stegmaier and H. Ziegler	978	Magnitude and time trends of the life-time risk of developing cancer in Saarland, Germany
E. Boven, H. M. M. Schlüper, C. A. M. Erkelens and H. M. Pinedo	983	Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer
Feature Articles		
P. L. Weiden	987	Do perioperative blood transfusions increase the risk of cancer recurrence?
M. Dowsett	989	Novel approaches to the endocrine therapy of breast cancer
Science Watchers		
M. S. Palmer	992	Mammalian sex determination
Book Reviews		
P. M. Stell	994	*Cancer of the Head and Neck*. Edited by E. N. Myers and J. Y. Suen
N. M. Breach	994	*Microsurgical Reconstruction of the Head and Neck*. Edited by Shan D. Baker
News	995	
Letters		
M. A. Burton, D. K. Kelleher, B. N. Gray and C. K. Morgan	999	Effect of temperature on liver tumour blood flow
M. A. Burton, D. K. Kelleher, J. P. Codde and B. N. Gray	1000	Hepatic thermochemotherapy
V. Ventafridda, C. Ripamonti, M. Tamburini, R. B. Cassileth and F. De Conno	1000	Unendurable symptoms as prognostic indicators of impending death in terminal cancer patients
A. Najid	1001	Aromatisation of dehydroepiandrosterone by hormone dependent human mammary cancer MCF-7 subcellular fractions
A. S. Alberts, G. Falkson and L. van Zyl	1002	Ifosfamide and mesna with doxorubicin have activity in malignant mesothelioma
	1002	Correction
Meeting Abstracts	1003	Advances in the Applications of Monoclonal Antibodies in Clinical Oncology: 7th International Meeting, London, 1990

NUMBER 10

Comments and Critique		
R.D. Rubens	1023	Auditing palliative cancer chemotherapy
M. Lipsedge, A.B. Summerfield, C. Ball and J.P. Watson	1025	Digitised video and the care of outpatients with cancer
Papers		
M.S. Naylor, S.T.A. Malik, G.W.H. Stamp, T. Jobling and F.R. Balkwill	1027	*In situ* detection of tumour necrosis factor in human ovarian cancer specimens
S.T.A. Malik, M.S. Naylor, N. East, A. Oliff and F.R. Balkwill	1031	Cells secreting tumour necrosis factor show enhanced metastasis in nude mice
Specialist Interest Articles		
S.M. O'Reilly, R.S. Camplejohn, R.R. Millis, R.D. Rubens and M.A. Richards	1035	Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer
G.M. Kiebert, J.H.C.J.M. de Haes, J. Kievit and C.J.H. van de Velde	1038	Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer
W.V. Bogomoletz, C. Pourny and B. Didier	1042	Argyrophilic nuclear organiser region counts in locally advanced breast carcinoma treated by chemotherapy before surgery

M. Shirai, S. Watanabe and M. Nishioka	1045	Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report
O.S. Nielsen, A.J. Munro, W. Duncan, J. Sturgeon, M.K. Gospodarowicz, M.A.S. Jewett, A. Malkin and G.M. Thomas	1049	Is placental alkaline phosphatase (PLAP) a useful marker for seminoma?
N. Tsavaris, Ch. Bacoyannis, N. Milonakis, M. Sarafidou, N. Zamanis, D. Magoulas and P. Kosmidis	1054	Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma
H. Kreisman, M. Goutsou, C. Modeas, S.L. Graziano, M.E. Costanza and M.R. Green	1057	Cisplatin–carboplatin therapy in extensive non-small cell lung cancer: a Cancer and Leukemia Group B study
P.K. Lipponen, M.J. Eskelinen and M. Sotarauta	1060	Prediction of superficial bladder cancer by histoquantitative methods
J.S. Cebon, R.W. Bury, G.J. Lieschke and G. Morstyn	1064	The effects of dose and route of administration on the pharmacokinetics of granulocyte–macrophage colony-stimulating factor
M. Joraschkewitz, H. Depenbrock, M. Freund, G. Erdmann, H.-J. Meyer, W. De Riese, D. Neukam, U. Hanauske, M. Krumwieh, H. Poliwoda and A.-R. Hanauske	1070	Effects of cytokines on *in vitro* colony formation of primary human tumour specimens
D.E. Bechard, R.P. Fairman, D.B. Hinshaw, A.A. Fowler and F.L. Glauser	1074	*In vivo* interleukin-2 activated sheep lung lymph lymphocytes increase ovine vascular endothelial permeability by non-lytic mechanisms
G. Pratesi, M. Rodolfo, G. Rovetta and G. Parmiani	1079	Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid
P.L.-E. Daneryd, L.R. Hafström and I.H. Karlberg	1083	Effects of spontaneous physical exercise on experimental cancer anorexia and cachexia
M. Iigo, K. Nishikata, Y. Nakajima, A. Hoshi and E. De Clercq	1089	Effect of (*E*)-5-(2-bromovinyl)-2′-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases

Feature Articles

T.A.W. Splinter	1093	Chemotherapy in advanced non-small cell lung cancer
M.J.S. Dyer	1099	The new genetics and non-Hodgkin lymphoma

Book Review

J. Ninane	1103	*Long-term Complications of Therapy for Cancer in Childhood and Adolescence* by D.M. Green

News 1103

Letters

I. Okpala	1105	Contrasting sex distribution of chronic lymphocytic leukaemia and well-differentiated diffuse lymphocytic lymphoma in Ibadan, Nigeria
A. Pines, L. Bat and E. Shemesh	1105	Colorectal cancerous polyps compared with benign adenomas
N. Matsuhashi, T. Moriyama, I. Nakamura, T. Ishikawa, S. Ohnishi, H. Nakagama, M. Imawari and F. Takaku	1106	Adoptive immunotherapy of primary and metastatic liver cancer via hepatic artery catheter
J. Soga, T. Suzuki, K. Yoshikawa, H. Katoh, Y. Tsuno and T. Muto	1107	Carcinoid somatostatinoma of the duodenum
P. Preusser, H. Wilke, W. Achterrath, L. Lenaz, M. Stahl, J. Casper, H.-J. Meyer, J. Meyer, M. Blum and H.J. Schmoll	1108	Phase II study of carboplatin in untreated inoperable advanced stomach cancer
P.C. Huijgens, R.S. van Schijndel, I. Kampman, G.J. Ossenkoppele, M. Klomp-Gerringa and E. van der Putten	1109	Untunnelled subclavian vein catheters in haemato-oncology patients

NUMBER 11/12

Comments and Critique

C. S. Muir and P. Boyle — 1111 — The burden of cancer in Europe

A. Jacobs — 1113 — The myelodysplastic syndrome

G. Cimino — 1115 — Chemotherapy alone for the treatment of early-stage Hodgkin's disease

Fax Communication

S. Bastuji-Garin, S. Richardson and R. Zittoun — 1119 — Acute leukaemia in workers exposed to electromagnetic fields

Papers

V. E. Gould, W. H. Warren, L. P. Faber, C. Kuhn and W. W. Franke — 1121 — Malignant cells of epithelial phenotype limited to thoracic lymph nodes

J. F. R. Robertson, D. Pearson, M. R. Price, C. Selby, R. A. Badley, J. Pearson, R. W. Blamey and A. Howell — 1127 — Assessment of four monoclonal antibodies as serum markers in breast cancer

Specialist Interest Articles

S. D. Fossá, N. K. Aaronson, D. Newling, P. J. van Cangh, L. Denis, K.-H. Kurth, M. de Pauw and the members of the EORTC Genito-Urinary Group — 1133 — Quality of life and treatment of hormone resistant metastatic prostatic cancer

A. Martoni, B. Melotti, M. Guaraldi, M. A. Pacciarini, A. Riva and F. Pannuti — 1137 — High-dose epirubicin for untreated patients with advanced tumours: a phase I study

J. Wils, I. Utama, L. Sala, J. Smeets and A. Riva — 1140 — Phase II study of high-dose epirubicin in non-small cell lung cancer

G. P. M. ten Velde, B. T. M. J. Kuypers-Engelen, A. Volovics and F. T. Bosman — 1142 — Examination of bone marrow biopsy specimens and staging of small cell lung cancer

N. J. Bundred, H. J. Stewart, D. A. Shaw, A. P. M. Forrest and W. R. Miller — 1145 — Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancer

C.-M. Tsai, D. C. Ihde, C. Kadoyama, D. Venzon and A. F. Gazdar — 1148 — Correlation of *in vitro* drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival

S. Scalzo, A. Gengaro, G. Boccoli, R. Masciulli, G. Giannella, G. Salvo, P. Marolla, P. Carlini, G. Massimini, E. E. Holdener, U. Testa, F. Calabresi and C. Peschle — 1152 — Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

K. Mross, U. Mayer, T. Langenbuch, K. Hamm, K. Burk and D. Hossfeld — 1156 — Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients

Feature Articles

M. J. E. Sternberg and M. J. J. M. Zvelebil — 1163 — Prediction of protein structure from sequence

O. M. Jensen, J. Estève, H. Møller and H. Renard — 1167 — Cancer in the European Community and its member states

News — 1257

Letters

S. Kohnoe, Y. Emi, Y. Sakaguchi, Y. Maehara, T. Kusumoto and K. Sugimachi — 1260 — The microtitre succinate dehydrogenase inhibition test for chemosensitivity of human tumour cells

H. Bleiberg, D. Becquart, J. Michel, F. Cavalli and B. Gerard — 1260 — Phase II trial of fotemustine in advanced colorectal cancer

S. Tokudome — 1261 — Adult T-cell leukaemia/lymphoma and horizontally transmitted human T-lymphotropic virus type I

C. Barone, A. Cassano and A. Astone — 1262 — Toxic epidermal necrolysis during chlorambucil therapy in chronic lymphocytic leukaemia

S. G. Ayre, D. Perez Garcia y Bellon and D. Perez Garcia Jr — 1262 — Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas

Supplement 1

S. B. Kaye	S1	Introduction
Review		
R. A. Joss, B. C. Brand, K. S. Buser and T. Cerny	S2	The symptomatic control of cytosatic drug-induced emesis. A recent history and review
Animal Pharmacology		
P. R. Blower	S8	The role of specific 5-HT_3 receptor antagonism in the control of cytostatic drug-induced emesis
Human Pharmacology		
J. W. Upward, B. D. C. Arnold, C. Link, D. M. Pierce, A. Allen and T. C. G. Tasker	S12	The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT_3 antagonist
Clinical Pharmacology		
M. Soukop on behalf of the Granisetron Study Group	S15	A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin
I. E. Smith on behalf of the Granisetron Study Group	S19	A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy
D. R. Cupissol, B. Serrou and M. Caubel	S23	The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis
M. Marty on behalf of the Granisetron Study Group	S28	A comparative study of the use of granisetron, a selective 5-HT_3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis
B. Chevallier on behalf of the Granisetron Study Group	S33	Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study
Overview		
M. V. Tabona	S37	An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy
Summary		
F. Oberling	S42	Concluding Remarks
Panel Discussion	S42	All speakers